CY1120351T1 - Μεθοδος και συνθεση για την αγωγη της οφθαλμικης υπερτασεως και του γλαυκωματος - Google Patents

Μεθοδος και συνθεση για την αγωγη της οφθαλμικης υπερτασεως και του γλαυκωματος

Info

Publication number
CY1120351T1
CY1120351T1 CY20171100675T CY171100675T CY1120351T1 CY 1120351 T1 CY1120351 T1 CY 1120351T1 CY 20171100675 T CY20171100675 T CY 20171100675T CY 171100675 T CY171100675 T CY 171100675T CY 1120351 T1 CY1120351 T1 CY 1120351T1
Authority
CY
Cyprus
Prior art keywords
glaucoma
treatment
hyperence
eye
composition
Prior art date
Application number
CY20171100675T
Other languages
English (en)
Inventor
Timo Reunamaki
Pertti Pellinen
Olli Oksala
Kari Lehmussaari
Original Assignee
Santen Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120351(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co., Ltd filed Critical Santen Pharmaceutical Co., Ltd
Publication of CY1120351T1 publication Critical patent/CY1120351T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ένα οφθαλμικό υδατικό διάλυμα για την αγωγή της οφθαλμικής υπερτάσεως και του γλαυκώματος, το οποίο περιλαμβάνει ανάλογο της PGF2a ως δραστικό συστατικό, όπου το εν λόγω οφθαλμικό υδατικό διάλυμα περιέχει μη ιοντικό επιφανειοδραστικό, σταθεροποιητικό παράγοντα και ουσιαστικά δεν περιλαμβάνει συντηρητικά εντός ενός περιέκτη αποτελούμενου ουσιαστικά από πολυαιθυλένιο· και το πολυαιθυλένιο είναι πολυαιθυλένιο χαμηλής πυκνότητας (LDPE).
CY20171100675T 2008-05-30 2017-06-27 Μεθοδος και συνθεση για την αγωγη της οφθαλμικης υπερτασεως και του γλαυκωματος CY1120351T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma
EP14001862.3A EP2772249B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP09754864.8A EP2306977B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
CY1120351T1 true CY1120351T1 (el) 2019-07-10

Family

ID=39940592

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100763T CY1115565T1 (el) 2008-05-30 2014-09-18 Μεθοδος και συνθεση για την αγωγη της οφθαλμικης υπερτασεως και του γλαυκωματος
CY20171100675T CY1120351T1 (el) 2008-05-30 2017-06-27 Μεθοδος και συνθεση για την αγωγη της οφθαλμικης υπερτασεως και του γλαυκωματος

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20141100763T CY1115565T1 (el) 2008-05-30 2014-09-18 Μεθοδος και συνθεση για την αγωγη της οφθαλμικης υπερτασεως και του γλαυκωματος

Country Status (27)

Country Link
US (3) US9999593B2 (el)
EP (7) EP2127638A1 (el)
JP (9) JP2011521943A (el)
KR (5) KR101650006B1 (el)
CN (1) CN102083413B (el)
AR (2) AR071937A1 (el)
AU (1) AU2009252210C1 (el)
BR (1) BRPI0913109B8 (el)
CA (2) CA2724194C (el)
CY (2) CY1115565T1 (el)
DK (4) DK2306977T3 (el)
EA (1) EA023661B1 (el)
ES (5) ES2808050T3 (el)
GE (1) GEP20156220B (el)
HR (4) HRP20220361T1 (el)
HU (3) HUE033103T2 (el)
JO (1) JO3039B1 (el)
LT (3) LT2772249T (el)
MX (1) MX2010012987A (el)
MY (1) MY159463A (el)
PL (4) PL2772249T3 (el)
PT (4) PT3205334T (el)
SG (1) SG191628A1 (el)
SI (4) SI3714877T1 (el)
TW (1) TWI432202B (el)
UA (1) UA102257C2 (el)
WO (1) WO2009145356A1 (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
AU2011282681B2 (en) * 2010-07-29 2015-07-30 Allergan, Inc. Preservative free bimatoprost and timolol solutions
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
EP2598117A2 (en) * 2010-07-29 2013-06-05 Allergan, Inc. Preservative free bimatoprost solutions
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
EP2618810B1 (en) 2010-09-21 2016-11-23 S & V Technologies GmbH Cosmetic composition
EP2452669A1 (en) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
WO2012141334A1 (en) * 2011-04-12 2012-10-18 R-Tech Ueno, Ltd. Aqueous ophthalmic composition
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
FI2887923T3 (fi) * 2012-08-24 2023-06-30 Sun Pharmaceutical Ind Ltd Polyoksylilipidin tai polyoksylirasvahapon oftalminen formulaatio ja silmätilojen hoito
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9913849B2 (en) 2014-01-10 2018-03-13 Manistee Partners Llc Treatment of migraines
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
EP3103439B1 (en) 2015-06-09 2019-08-07 MEDproject Pharma-Entwicklungs- und Vertriebsgesellschaft mbH Drippable ophthalmic bimatoprost gel
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
CA3004587A1 (en) * 2015-11-06 2017-05-11 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
BR112018067946A8 (pt) 2016-02-29 2022-11-08 Sun Pharma Global Fze Formulações tópicas contendo ciclosporina e usos das mesmas
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
ES2972844T3 (es) * 2017-03-27 2024-06-17 Alcon Inc Preparación farmacéutica
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
EP3643297A4 (en) 2017-06-22 2021-03-17 Yonsung Fine Chemical Co., Ltd. OPHTHALMIC COMPOSITION FOR GLUCOMA TREATMENT
CN111479568A (zh) * 2017-12-21 2020-07-31 参天制药株式会社 司培前列素与Rho激酶抑制剂的组合药物
WO2020013717A1 (en) 2018-07-09 2020-01-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Ophthalmic dispensing device
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
WO2023182480A1 (ja) * 2022-03-25 2023-09-28 株式会社坪田ラボ 水性組成物
WO2023241652A1 (zh) * 2022-06-16 2023-12-21 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
EP0286903B2 (en) 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AU704938B2 (en) * 1995-11-17 1999-05-06 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
DE69714274T3 (de) 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
WO1998025829A1 (en) 1996-12-09 1998-06-18 Bausch & Lomb Incorporated Single-use flexible container
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
EP0979652B1 (en) 1997-10-13 2006-05-24 R-Tech Ueno, Ltd. Remedial composition for intraocular hypertension or glaucoma
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
WO2000003736A1 (en) 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Prostaglandin product
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
JP2003517441A (ja) 1998-09-25 2003-05-27 アルコン ラボラトリーズ， インコーポレイテッド 徐放性で快適な眼疾病用組成物および眼疾病の治療方法
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
PL350924A1 (en) 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
AU2001264261A1 (en) 2000-06-19 2002-01-02 Santen Pharmaceutical Co. Ltd. Aseptics
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
DK1321144T3 (da) 2000-09-13 2011-03-07 Santen Pharmaceutical Co Ltd Øjendråber
TW586946B (en) 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
AU2003248070A1 (en) 2002-07-16 2004-02-02 Hanshin Yoki Co., Ltd. Chemical container and method of manufacturing the container
KR101253941B1 (ko) 2002-09-09 2013-04-16 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
EP1666043B1 (en) 2003-07-31 2009-12-02 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
US20050287325A1 (en) 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
ATE412400T1 (de) 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
WO2007042262A2 (en) 2005-10-10 2007-04-19 Novagali Pharma Sa Ophthalmic emulsions containing prostaglandins
WO2006058139A2 (en) 2004-11-24 2006-06-01 Holopack International Corp. Dispensing container with flow control system
CN102526064A (zh) * 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的***素的制品
DK1829545T3 (da) 2004-12-24 2012-07-23 Santen Pharmaceutical Co Ltd Produkter indeholdende prostaglandin-F2alfa-derivat
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
WO2007007832A1 (ja) 2005-07-13 2007-01-18 Santen Pharmaceutical Co., Ltd. 眼科用防腐組成物
US8030349B2 (en) 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
MY159463A (en) 2017-01-13
CA2724194C (en) 2017-06-27
PT3205334T (pt) 2020-07-31
EP3714877A1 (en) 2020-09-30
US20210059931A1 (en) 2021-03-04
PL3714877T3 (pl) 2022-05-16
JP2011521943A (ja) 2011-07-28
EP4035656B1 (en) 2023-11-22
TW201000104A (en) 2010-01-01
US9999593B2 (en) 2018-06-19
US10864159B2 (en) 2020-12-15
ES2495316T3 (es) 2014-09-17
DK2772249T3 (en) 2017-07-17
CA2965185A1 (en) 2009-12-03
KR101650006B1 (ko) 2016-08-22
JP2018154656A (ja) 2018-10-04
DK3205334T3 (da) 2020-07-13
EP2772249B1 (en) 2017-05-03
CN102083413A (zh) 2011-06-01
SG191628A1 (en) 2013-07-31
US20110152264A1 (en) 2011-06-23
EP3205334B1 (en) 2020-04-29
KR20200057801A (ko) 2020-05-26
HRP20200998T1 (hr) 2020-10-16
HRP20140979T1 (hr) 2014-11-21
EP2306977B1 (en) 2014-08-13
HUE033103T2 (en) 2017-11-28
JP6148317B2 (ja) 2017-06-14
BRPI0913109B8 (pt) 2021-05-25
EP2127638A1 (en) 2009-12-02
JP6889789B2 (ja) 2021-06-18
HUE049923T2 (hu) 2020-11-30
JP7265584B2 (ja) 2023-04-26
JP2017178957A (ja) 2017-10-05
SI3714877T1 (sl) 2022-05-31
EP3205334A1 (en) 2017-08-16
LT3205334T (lt) 2020-09-25
CA2724194A1 (en) 2009-12-03
JP2023085558A (ja) 2023-06-20
EA201071413A1 (ru) 2011-06-30
ES2627837T8 (es) 2018-02-26
AU2009252210A1 (en) 2009-12-03
JO3039B1 (ar) 2016-09-05
WO2009145356A1 (en) 2009-12-03
EA023661B1 (ru) 2016-06-30
EP2306977A1 (en) 2011-04-13
ES2907982T3 (es) 2022-04-27
HRP20220361T1 (hr) 2022-05-13
CN102083413B (zh) 2013-11-06
KR102114401B1 (ko) 2020-05-25
JP7520285B2 (ja) 2024-07-23
BRPI0913109A2 (pt) 2017-06-20
EP4289446A3 (en) 2024-01-10
KR102246598B1 (ko) 2021-04-30
DK3714877T3 (da) 2022-02-14
AU2009252210C1 (en) 2016-04-14
PL3205334T3 (pl) 2020-11-02
ES2968837T3 (es) 2024-05-14
KR101820816B1 (ko) 2018-01-22
JP2016065095A (ja) 2016-04-28
LT2772249T (lt) 2017-09-11
KR20160102319A (ko) 2016-08-29
AU2009252210B2 (en) 2014-10-16
TWI432202B (zh) 2014-04-01
UA102257C2 (uk) 2013-06-25
AR071937A1 (es) 2010-07-28
PT3714877T (pt) 2022-03-10
SI2772249T1 (sl) 2017-08-31
PL2306977T3 (pl) 2015-01-30
BRPI0913109B1 (pt) 2019-10-22
PT2772249T (pt) 2017-08-08
JP6356868B2 (ja) 2018-07-11
MX2010012987A (es) 2011-02-24
EP2772249A1 (en) 2014-09-03
EP3714877B1 (en) 2022-01-26
LT3714877T (lt) 2022-04-11
HRP20170769T1 (hr) 2017-08-11
DK2306977T3 (da) 2014-09-15
AR120961A2 (es) 2022-04-06
CY1115565T1 (el) 2017-01-04
JP2020073574A (ja) 2020-05-14
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
PL2772249T3 (pl) 2017-10-31
HUE058079T2 (hu) 2022-06-28
US20180289618A1 (en) 2018-10-11
ES2808050T3 (es) 2021-02-25
JP2021120412A (ja) 2021-08-19
KR20180008905A (ko) 2018-01-24
ES2627837T3 (es) 2017-07-31
JP2024079852A (ja) 2024-06-11
JP2014133765A (ja) 2014-07-24
EP4035656A1 (en) 2022-08-03
KR101988642B1 (ko) 2019-06-12
JP6649992B2 (ja) 2020-02-19
KR20190067272A (ko) 2019-06-14
GEP20156220B (en) 2015-01-26
PT2306977E (pt) 2014-09-22
EP4289446A2 (en) 2023-12-13
KR20110011707A (ko) 2011-02-08

Similar Documents

Publication Publication Date Title
CY1120351T1 (el) Μεθοδος και συνθεση για την αγωγη της οφθαλμικης υπερτασεως και του γλαυκωματος
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
CL2017002883A1 (es) Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas
CR20110684A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
UA108641C2 (uk) Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
EA201171160A1 (ru) Производные атропоизомеров 2-пуринил-3-толилхиназолина и способы применения
ECSP066662A (es) Preparación farmacéutica que comprende un anticuerpo contra el receptor egf
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201100094A1 (ru) Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
WO2012162331A3 (en) Compositions comprising an efficient perfume bloom
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
AR065963A1 (es) Solucion acuosa de peroxido de hidrogeno, proceso para su preparacion y su uso
UY33097A (es) DERIVADOS DE (1h-PIRAZOL-5-IL)UREIDOARILO 1,3-DISUSTITUIDOS Y SUS USOS TERAPÉUTICOS
EA201100093A1 (ru) Тиадиазолилоксифениламидины и применение их в качестве фунгицидов
WO2007142618A3 (en) High concentrated, biocidally active compositions and aqueous mixtures and methods of making the same
CL2010001620A1 (es) Composicion agricola, del cuidado personal, del cuidado de la casa y de revestimiento que comprende silicona y otro componente adicional; emulsion acuosa y no acuosa que comprende la composicion agricola; y metodo para formular dichas composiciones (div. sol. n° 656-207).
CL2020002252A1 (es) Formulación oftálmica.
EA201891783A1 (ru) Композиция для растворения аморфных дитиазинов и способ ее применения
EA201291151A1 (ru) Жидкие композиции рупатадина фумарата
TW200738651A (en) Cyclohexyl sulfonamide derivatives
EA201301332A1 (ru) ОФТАЛЬМОЛОГИЧЕСКИЙ ПРЕПАРАТ, СОДЕРЖАЩИЙ АНАЛОГ PGF2α
EA201070483A1 (ru) Новые офтальмологические композиции
RS54378B1 (en) PROCEDURE FOR REDUCING EYE PRESSURE IN PEOPLE
CL2016003258A1 (es) Composiciones parasiticidas que comprenden derivados de indol, métodos y usos de las mismas.
CY1116359T1 (el) Μεθοδος για σταθεροποιηση s-νιτροζογλουταθειονης και συνθεση που παρασκευαζεται με αυτην